Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReabold Resources Regulatory News (RBD)

Share Price Information for Reabold Resources (RBD)

Share Price is delayed by 15 minutes
Get Live Data
81.00    0.00 (0.00%)
Bid:
80.00
Ask:
82.00
Spread: 2.00 (2.50%)
Market Cap: £11.75m
RBD Live PriceLast checked at - London Stock Exchange

Intraday Reabold Resources Share Chart

Contract Gain

14 Feb 2006 07:01

Adventis Group PLC14 February 2006 For release 07.00am 14 February 2006 Adventis Group plc Contract Gain Adventis, the specialist multimedia marketing and advertising agency, announcesthat Affiniti (UK) Ltd, its Bucks-based healthcare agency has been awarded theZanidip account following a three-way pitch. The contract, for an undisclosedamount, is now live. Zanidip (lercanidipine), a highly effective calcium blocker used by GP's tolower blood pressure in the treatment of hyper tension, was originally licensedout but the Italian multi-national pharmaceutical group Recordati S.p.A. has nowopened a UK marketing office and will henceforward market the drug itself. Highblood pressure is a problem most common in the elderly, related to poor controlof the working of the heart, and for kidney and liver diseases. Although Affiniti has been involved before in marketing the Zanidip brand,Recordati were looking for a completely fresh approach to move the productforward. Martin Symons, Recordati's UK General Manager, commented: "It was by no means aforegone conclusion for Affiniti - they had to perform on an even playing fieldagainst good competitors, but they came through very strongly. We look forwardto working with them to develop a strong campaign that will move Zanidip to itsrightful position in the marketplace." Affiniti has also won three other pitches against major league competition: - A major product launch for MabThera in severe rheumatoid arthritis for Roche - A major new European campaign in glaucoma for Allergan's Lumigan - A new campaign for Periostat, a dental root treatment for Alliance Said Affiniti's Managing Director, Stuart Tennant: "Across all these recentpitches we have been up against some of the UK's leading healthcare agencieswith big creative reputations - so we know we can compete at the top level. Weare continuing to build our team, our clients' brands - and a strong reputationof our own." - ENDS - Editor's Notes Adventis Group plc is an AIM listed, full service marketing and advertisingagency, providing services to the property, healthcare and financial servicesindustries. Through its six operating companies the company provides a complete range ofcommunication services, including corporate identity programmes, advertisingcampaigns, media planning & buying, literature, public relation, packaging,exhibitions, research and planning, interiors, signage and digital media. Adventis employs over 80 staff in London and the South East. www.adventis.co.uk Recordati is a European pharmaceutical group mainly dedicated to the research,development, manufacturing and marketing of pharmaceuticals. Headquartered inMilan, it has operations in France, Germany, Greece, Ireland, Italy, Spain,Switzerland, the United Kingdom and the United States. Recordati has been listedon the Italian Stock Exchange since 1984. www.recordati.com Enquiries: Affiniti (UK) LtdStuart Tennant, Managing Director 01494 775 213 Adventis Group plc Charles Phillpot, Chief Executive Officer 020 7034 4750 Seymour PierceJohn Depasquale 020 7107 8000 Binns & Co PR Ltd 020 7786 9600Peter Binns / 07768 392 582Annie Evangeli 07778 507 162 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Jul 20185:09 pmRNSHolding(s) in Company
29th Jun 201812:56 pmRNSResult of GM, and Acquisition of Gaelic Resources
29th Jun 20187:00 amRNSAnnual Report and Financial Statements 2017
22nd Jun 20184:44 pmRNSGeneral Meeting
15th Jun 201810:10 amRNSCompany Presentation
14th Jun 20187:00 amRNSAcquisition of Gaelic Resources and Notice of GM
4th Jun 20187:00 amRNSCPR on Corallian owned Oulton Appraisal Project
30th May 201812:38 pmRNSFinal tranche of investment in Corallian Energy
29th May 20182:02 pmRNSHolding(s) in Company
23rd May 20183:56 pmRNSCorallian 30th Seaward Licensing Round Award
15th May 20187:00 amRNSUpdate on Colter and Wick Projects
3rd Apr 20185:03 pmRNSTotal Voting Rights
3rd Apr 20183:35 pmRNSHolding(s) in Company
28th Mar 20189:46 amRNSFirst tranche of investment in Danube Petroleum
27th Mar 20183:45 pmRNSHolding(s) in Company
22nd Mar 201812:49 pmRNSHolding(s) in Company
21st Mar 20185:13 pmRNSHolding(s) in Company
19th Mar 20181:13 pmRNSResult of General Meeting, Issue of Equity, TVR
14th Mar 20184:24 pmRNSIssue of Options
2nd Mar 20186:04 pmRNSPosting of Circular
1st Mar 201811:30 amRNSIncreased Investment in Corallian Energy
28th Feb 20185:11 pmRNSResult of the Placing
28th Feb 201811:26 amRNSConditional Accelerated Bookbuild
27th Feb 201812:30 pmRNSCompany Update regarding the P2235 "Wick" Licence
26th Feb 20181:24 pmRNSStatement re Press Comment
12th Feb 20189:49 amRNSIntention to increase Corallian Energy investment
24th Jan 20185:20 pmRNSHolding(s) in Company
16th Jan 201811:16 amRNSUpdate on UK oil and gas assets
4th Dec 20177:00 amRNSInvestment in Danube Petroleum Limited
14th Nov 20177:00 amRNSPresentation at Investor Evening
1st Nov 20177:00 amRNSInvestment in UK oil and gas assets
27th Oct 20174:19 pmRNSHolding in Company
27th Oct 20179:12 amRNSHolding(s) in Company
19th Oct 20175:48 pmRNSBoard appointments and Issue of Options
16th Oct 20175:29 pmRNSHolding(s) in Company
12th Oct 201712:26 pmRNSResult of General Meeting, Issue of Equity, TVR
9th Oct 20177:00 amRNSSenior Management Appointments
2nd Oct 20174:35 pmRNSProposed subscription to raise £1.76 million
25th Sep 20173:37 pmRNSHolding(s) in Company
22nd Sep 20177:00 amRNSNotice of GM
20th Sep 20177:00 amRNSPlacing to raise £3.96m, update on strategy, TVR
19th Sep 20175:16 pmRNSHalf-year Report
14th Sep 20177:00 amRNSStmnt re Share Price Movement
16th Aug 20171:02 pmRNSResult of AGM
21st Jul 20176:02 pmRNSNotice of AGM
26th Jun 20175:44 pmRNSAnnual Report for year ended 31 December 2016
1st Jun 20178:01 amRNSInvestee company update: process metallurgy
30th May 20177:00 amRNSInvestee Company Update
25th May 20177:00 amRNSInvestee Company Update
2nd May 20174:25 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.